Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 4/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.68 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.68 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.68 |
| ▸ | LDHA | P00338 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | FBP1 | P09467 | 1/20 | 0.68 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.68 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.68 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.68 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723484 | 0.91 | P2RY1 (0.70) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL381173 | 0.90 | P2RY1 (0.66) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL4356493 | 0.90 | P2RY1 (0.66) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL1000175 | 0.90 | P2RY1 (0.68) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL8708990 | 0.89 | ADORA1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL6569310 | 0.88 | ADORA1 (0.73) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL219554 | 0.88 | P2RY1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL11584743 | 0.88 | P2RY1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL31001632 | 0.88 | P2RY1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC | |
| SCHEMBL5550634 | 0.88 | P2RY1 (0.71) | P2RY1ADORA1P2RY2SMN1; SMN2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272897-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2003-01-08 | — | — | EP | claimed |
| WO-2001058241-A9 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2002-10-17 | — | — | WO | claimed |
| WO-2001058241-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2001-08-16 | — | — | WO | claimed |
| US-10822587-B2 | T cell balance gene expression, compositions of matters and methods of use thereof | THE BROAD INSTITUTE, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200081017-A1 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-03-12 | — | — | US | disclosed |
| EP-3368048-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | Ultragenyx Pharmaceutical Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075540-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AMYLOIDOSIS | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-3110971-A2 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-20150361396-A1 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | THE BROAD INSTITUTE, INC. | 2015-12-17 | — | — | US | disclosed |
| WO-2015130968-A2 | T CELL BALANCE GENE EXPRESSION, COMPOSITIONS OF MATTERS AND METHODS OF USE THEREOF | The Broad Institute Inc. (US) | 2015-09-03 | — | — | WO | disclosed |
| EP-0991414-A4 | METHODS AND COMPOSITIONS FOR REDUCING ISCHEMIC INJURY OF THE HEART BY ADMINISTERING ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001058241-A2 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | NEW YORK UNIVERSITY (US) | 2001-08-16 | — | — | WO | disclosed |
| US-6211165-B1 | GENE EXPRESSION; BINARY CONJUGATES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2001-04-03 | — | — | US | disclosed |
| EP-0991414-A1 | METHODS AND COMPOSITIONS FOR REDUCING ISCHEMIC INJURY OF THE HEART BY ADMINISTERING ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0966285-A1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | Cerebrus Pharmaceuticals Limited (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998050047-A1 | METHODS AND COMPOSITIONS FOR REDUCING ISCHEMIC INJURY OF THE HEART BY ADMINISTERING ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998039003-A1 | USE OF (+)MEFLOQUINE FOR THE TREATMENT OF MALARIA | CEREBRUS LIMITED (GB) | 1998-09-11 | — | — | WO | disclosed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | disclosed |
| US-4167565-A | Adenosine-5'-carboxamides and method of use | ABBOTT LABORATORIES (US) | 1979-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | P2RY1 78/4885ADORA1 3/4885P2RY2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.